

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 424B3

XTL BIOPHARMACEUTICALS LTD

Form 424B3

January 19, 2010

January 15, 2010

Securities & exchange Commission
450 Fifth Street, NW
Washington, DC 20549

Attn.: Document Control

RE: American Depositary Shares
evidenced by the American
Depositary Receipts each
representing Ten (10)
Ordinary Shares of XTL
Biopharmaceuticals Ltd.
(Form F-6 File No. 333-
147677)

Ladies and Gentlemen:

Pursuant to Rule 424(b)(3) under the
Securities Act of 1933, as amended, on
behalf of The Bank of New York, as
Depositary for securities against which
American Depositary Receipts are to be
issued, we attach a copy of the new
prospectus (Prospectus) reflecting in number
of ordinary shares represented by one
American Depositary Share (the Ratio).

As required by Rule 424(e), the upper right
hand corner of the Prospectus cover page has
a reference to Rule 424(b)(3) and to the file
number of the registration statement to which
the Prospectus relates.

Pursuant to Section III B of the General
Instructions to the Form F-6 Registration
Statement, the Prospectus consists of the
ADR certificate with revised ratio and par
value for XTL Biopharmaceuticals Ltd.

The Prospectus has been revised to reflect
the new par value and ratio, and has been
overstamped with:

Effective June 22, 2009 the Companys
American Depositary Share (ADS) Ratio
Changed from 1:10 (One ADS
Representing Ten Ordinary Shares to 1:2
(One ADS Representing Two Ordinary
Shares) and the Par Value Changed from
ILS 0.02 to ILS 0.10.

Please contact me with any questions or

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 424B3

comments at 212 815-8223

Agness Moskovits
Assistant Vice President
The Bank of New York Mellon - ADR
Division
Encl.
CC: Paul Dudek, Esq. (Office of International
Corporate Finance)

101 Barclay Street, New York NY 10286